Febuxostat Tablet
FDA Label NDC 27808-206

37 label sections · Submitted to the FDA by Tris Pharma Inc · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Tris Pharma Inc for the product Febuxostat (NDC 27808-206). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: cardiovascular death, 1 indications and usage, 2.1 recommended dosage, 2.2 dosage recommendations in patients with renal impairment and hepatic impairment, 2.3 serum uric acid level monitoring, 2.4 recommended prophylaxis for gout flares, 3 dosage forms and strengths, 4 contraindications, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

* Please review the disclaimer below.